Terns to Present at the 19th Annual Virtual Needham HealthCare Conference
April 07 2021 - 7:05AM
Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq:
TERN), a clinical-stage biopharmaceutical company developing a
portfolio of small-molecule single-agent and combination therapy
candidates for the treatment of non-alcoholic steatohepatitis
(NASH) and other chronic liver diseases, today announced that
management will be presenting at the 19th Annual Virtual Needham
Healthcare Conference on Wednesday, April 14 at 11:40 a.m. ET.
A live audio webcast of the presentation will be available on
the conference website and on Terns’ website. A replay of the
webcast will be archived on Terns’ website for 30 days following
the presentation.
About Terns PharmaceuticalsTerns
Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
developing a portfolio of small-molecule single-agent and
combination therapy candidates for the treatment of non-alcoholic
steatohepatitis, or NASH, and other chronic liver diseases. Terns’
programs are based on clinically validated and complementary
mechanisms of action to address the multiple hepatic disease
processes of NASH in order to drive meaningful clinical benefits
for patients. For more information, please visit
www.ternspharma.com.
Contacts for Terns
InvestorsMark Vignola
investors@ternspharma.com
Media Cory Trombleemedia@ternspharma.com
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From Apr 2023 to Apr 2024